ROIV
HealthcareRoivant Sciences Ltd. · Biotechnology · $22B
What is Roivant Sciences Ltd.?
Roivant Sciences is a London-based biopharmaceutical and healthcare technology company focused on researching and developing medicines across a broad range of therapeutic areas.
Roivant advances drug candidates targeting conditions such as solid tumors, sickle cell disease, autoimmune disorders, and dermatological conditions including psoriasis, atopic dermatitis, and vitiligo. The company operates through a distinctive 'vant' model, creating subsidiaries to develop individual therapeutic programs, aiming to bring medicines to patients more efficiently.
The company was founded in 2014 and is headquartered in London, United Kingdom.
- Oncology pipeline candidates
- Immunology and autoimmune therapies
- Dermatology treatments
- Rare disease programs
Is ROIV a Good Stock to Buy?
UQS Score rates ROIV as Poor overall.
Among the five pillars, Risk stands out as the relative bright spot, suggesting the company carries a more manageable risk profile than its overall score might imply. This may reflect its diversified pipeline structure across multiple therapeutic areas.
Quality, Moat, and Growth all register as Weak, and Valuation is rated Elevated — a combination that warrants careful scrutiny from investors.
Sign up to see the full pillar breakdown and detailed financial metrics behind the ROIV rating. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ROIV pay dividends?
No — Roivant Sciences Ltd. does not currently pay a dividend.
Roivant Sciences does not currently pay a dividend. As a clinical-stage biopharmaceutical company, capital is directed toward pipeline development and research rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does ROIV report earnings?
Roivant Sciences reports earnings on a quarterly cadence, consistent with US-listed equities.
Given the company's clinical-stage focus, quarterly results tend to center on pipeline progress and cash runway rather than revenue growth. Investors should monitor pipeline milestones alongside financial disclosures.
For the most recent quarter's results, visit Roivant Sciences' investor relations page directly.
ROIV Price History
+197.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Roivant Sciences Ltd.?
Based on Roivant Sciences Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Roivant Sciences do?
Roivant Sciences researches and develops medicines across oncology, immunology, rare diseases, and dermatology. It uses a subsidiary-based 'vant' model to advance individual drug programs, aiming to bring treatments to patients more efficiently than traditional pharma structures.
Does ROIV pay dividends?
No, ROIV does not pay a dividend. The company reinvests available capital into its clinical pipeline and research operations. Investors seeking regular income should look elsewhere in the healthcare sector.
When does ROIV report earnings?
Roivant Sciences reports on a quarterly basis. Because our data source does not cover specific upcoming dates, check the company's investor relations page for the latest earnings schedule.
Is ROIV a good stock to buy?
UQS Score rates ROIV as Poor, with Weak readings across Quality, Moat, and Growth, and an Elevated Valuation. Risk is the one relatively stronger pillar. Pro members can access the complete pillar breakdown to form a more informed view.
Is ROIV overvalued?
The UQS Valuation pillar for ROIV is rated Elevated, suggesting the current price may not fully reflect the company's underlying fundamentals. Clinical-stage biotechs often carry premium valuations tied to pipeline potential rather than current earnings.
What is ROIV's market cap bracket?
Roivant Sciences is classified as a large-cap company, placing it among the larger players in the biopharmaceutical development space despite its clinical-stage profile.
Who founded Roivant Sciences?
Roivant Sciences was founded by Vivek Ramaswamy, who established the company with the goal of reimagining how medicines are developed and commercialized through a decentralized subsidiary model.
Is ROIV a long-term quality investment?
As a long-term quality indicator, ROIV's current UQS profile — with Weak Quality, Moat, and Growth pillars — suggests meaningful hurdles remain. Pipeline execution and clinical trial outcomes will be key determinants of whether the quality profile improves over time.
Unlock Full ROIV Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for ROIV
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare ROIV against peers in the biopharmaceutical sector
- ✓Track quality score changes as new data becomes available
Pro Analysis
ROIV — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 19.1 | 0.0 | 18.0 | 37.5 | 47.1 | 0.0 | +5.1 |
| Apr 2, 2026 | 14.0 | 0.0 | 18.0 | 0.0 | 63.5 | 0.0 | — |
ROIV — Pillar Breakdown
Quality
— 0.0/100 (25%)Roivant Sciences Ltd. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 37.5/100 (20%)Roivant Sciences Ltd. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 65.6/100 (15%)Roivant Sciences Ltd. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Roivant Sciences Ltd. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 18/100 (25%)Roivant Sciences Ltd. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ROIV.
Score Composition
Financial Data
More Stock Analysis
How is the ROIV UQS Score Calculated?
The UQS (Unified Quality Score) for Roivant Sciences Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Roivant Sciences Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Roivant Sciences Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.